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Summary Hyperthermia for human gastric cancer xenotransplanted into the hindlegs of nude mice was
performed to determine whether misonidazole (MISO) or metronidazole (MTR), derivatives of nitroimidazole,
would intensify the antitumour effects of hyperthermia only, or combined with mitomycin C (MMC). MISO,
MTR and MMC were given i.p. at doses of 500mgkg-1, 500mgkg-1 and 2.Omgkg- respectively, and
MISO or MTR was administered 45min before MMC. Hyperthermia was applied twice at 48h intervals, by
means of a water bath at 43.5+0.1°C for 23min. Tumour tripling times following heat alone, MTR plus heat,
and MISO plus heat were about 6.7, 8.0 and 7.9 days respectively, compared with 4.6 days for the control,
but tumour regression occurred in the heat plus MISO group only. Tumour tripling times for MMC plus
heat, MMC plus MTR plus heat, and MMC plus MISO plus heat were 9.6, 11.6 and 17.1 days respectively,
compared to 4.6 days for the control and 6.7 days for heat alone. These data suggest that the antitumour
activity of MMC plus MISO plus heat is an additive phenomenon.
Hyperthermia combined with chemotherapy has proven to
be clinically effective for treating cancer. The cytotoxic effect
of some antitumour drugs is enhanced in proportion to the
elevation of temperature (Hahn, 1979; Dewey, 1984).
Although higher temperatures for extended times result in
greater antitumour efficacy, the host tolerance for hyper-
thermia becomes an insuperable limiting factor, particu-
larly in humans. We reported that the enhanced antitumour
efficacy of hyperthermia with a nitrosourea derivative is
brought about by polyamine antimetabolites (Fujimoto et
al., 1987). A nitroimidazole derivative has been widely
studied as a hypoxic radiosensitizer (Fowler & Denekamp,
1980). Much attention has focused on the derivative, misoni-
dazole (MISO) which is an excellent hypoxic radiosensitizer,
both in vitro and in vivo (Adams et al., 1976; Brown & Lee,
1980; Fowler & Denekamp, 1980; Stratford, 1982). Hyperth-
ermia, especially when the temperature exceeds 43°C, causes
a marked decrease in the tumour pO2, as the blood supply
and hence oxygenation are diminished (Urano & Kahn,
1983; Song, 1984). Apart from its radiosensitizing property,
a preclinical trial of MISO as a sensitizer in hyperthermo-
chemotherapy was carried out in an attempt to enhance the
antitumour activity of hyperthermochemotherapy in human
gastric cancer xenotransplanted into nude mice. Metroni-
dazole (MTR) which was first given to humans as a hypoxic
radiosensitizer (Urtasun et al., 1976), was added as a test
drug, because it is practically free from side effects in the
treatment of giardiais, especially infections of Trichomonas
vaginalis. Mitomycin C (MMC) was chosen as the anti-
tumour drug because of the significant enhancement of
MMC-induced cell killing by hyperthermia (Barlogie et al.,
1980; Shiu et al., 1983) as well as its wide use in the




BALB/c nu/nu mice (Japan Clea Laboratories, Tokyo,
Japan) aged 4 to 5 weeks were housed under aseptic
conditions and had free access to sterile food and water. A
human gastric cancer ST-2, obtained in 1980 from a 74 year
old woman was maintained in our laboratory by serial
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transplantation (Fujimoto et al., 1985b). A solid tumour
block (about 1 mm3) of ST-2 was inoculated bilaterally into
the external root in the hindlegs. The take rate was 98-100%
and spontaneous regression never occurred.
Treatment
When the ST-2 tumour was -150mm3 at 12 to 16 days
after the inoculation, treatment of 12 experimental groups
was begun. Mice were separated at random into groups of
19 to 29 animals. MISO, MTR and MMC were given i.p. at
doses of 500mgkg-1, 500mgkg-' and 2.0mgkg-1 respect-
ively, and MISO or MTR was given 45min before
MMC. Five minutes after the MMC injection, 50 mgkg 1 of
Nembutal (pentobarbital-Na: Abbott Laboratories, North
Chicago, ILL., USA) was injected i.p. Subsequently, the
right hindleg was placed in a water bath at 43.5+0.1°C, for
23min. This procedure was performed twice with a 48h
interval. Again, pentobarbital was administered to all experi-
mental groups in consideration of induction of hepatic drug-
metabolizing enzymes by barbiturates. Antitumour treat-
ments without hyperthermia were also performed twice with
a 48h interval. MISO and MTR were provided by Dr
Daniel F. Hoth (Division of Cancer Treatment, National
Cancer Inst., NIH, Bethesda, MD., USA) and Shionogi &
Co., Ltd. (Osaka, Japan) respectively. MMC was purchased
from Kyowa Hakko Co. Ltd. (Tokyo, Japan). The LD50 of
MMC in nude mice is 8.9mgkg 1 when given i.p. (Fujimoto
et al., 1985b).
Evaluation of treatment
Treatment was evaluated by observation of regression orf delay in tumour growth and estimate of tumour DNA
biosynthesis. In our previous studies with this ST-2 tumour
(Fujimoto et al., 1985b, 1986), tumour DNA biosynthesis
correlated well with tumour growth rate. Two perpendicular
diameters (length and width) of the inoculated tumour were
measured with vernier sliding calipers every other day, and
the tumour volume was calculated as 1/2 x ab2, where a and
b are the longest and shortest diameters respectively.
To assay the DNA biosynthesis in the ST-2 tumour,
tumour extirpation was performed 48h after the 2nd treat-
ment, and 1 h after i.p. injection of 3H-TdR (1.0pCig-1
body wt). 3H-TdR content was assayed in a liquid scintilla-
tion counter after digestion in a tissue solubilizer (Brown &
Badman, 1961; Winkelman & Slater, 1967). The accurately
weighed tumour was homogenized in ice-cold 0.3 NTCA and
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an acid-insoluble precipitate was obtained after centrifu-
gation at 4000 g for 15min. The previously neutralized
precipitate was solubilized by adding 1 ml aliquot of Proto-
sol, a tissue solubilizer (New England Nuclear, A Du Pont
Co., Boston, MA., USA). The solubilized samples were
assayed using a Wallac 1215 Rack Beta liquid scintillation
counter to determine the 3H-radioactivity. DNA biosynthesis
was calculated as cpmmg-1 wet wt.




Tumour tripling time, i.e., the time required to reach three
times the tumour volume at the first treatment, was calcu-
lated for 11 experimental groups. Results for 2 experiments
are shown in Table I and the mean and standard deviation
for each experiment are presented. No statistical difference
was found between experiments. Tumour tripling time in the
MTR only and MISO only groups was prolonged by 0.9 and
1.5 days respectively, compared to the control. Tumour
growth delay due to heat alone, heat plus MTR and heat
plus MISO was about 2.1, 3.4 and 3.3 days, but tumour
regression occurred only in the heat plus MISO group.
Tumour growth delays in the 3 groups given MMC only,
MMC plus MTR and MMC plus MISO were 0.6, 1.4 and
2.7 days respectively, with no tumour regressions.
In contrast, tumours exposed to heat and MMC exhibited
a transient regression and a growth delay of 2.9 days,
compared to those given heat alone. Similar results were seen
for heat treatment with MMC plus MTR. Hyperthermia
combined with MMC and MISO resulted in a 7.5 day delay,
in excess of that seen for heat plus MMC. The rate of
regrowth of tumours in groups given MMC plus heat,
MMC, MTR plus heat and MMC, MISO plus heat differed
little from the rate of regrowth for the other 8 groups.
DNA biosynthesis
Measurements of biosynthesis in the heat only, MIS only,
MTR only, MMC plus MISO and MMC plus MTR groups
did not differ from the control (Figure 1). Although DNA
biosynthesis of the MMC only group fell significantly com-
pared to the control (P=0.015), the two treatments with
MMC plus MISO or MMC plus MTR showed no signifi-
cant decrease (Figure 1). As shown in Figure 2, which shows
the biosynthesis of DNA following hyperthermia, hyper-
thermia only did not decrease tumour DNA biosynthesis,
while hyperthermia plus MISO did reduce it significantly
(P=0.020). DNA biosynthesis following hyperthermia plus









Figure 1 DNA biosynthesis in ST-2 tumour in the MTR,
MISO, heat only, MMC, MMC plus MTR and MMC plus
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Figure 2 DNA biosynthesis in ST-2 tumour given hyperthermia
with MTR, MISO or MMC. Each column and vertical bar
represents mean+s.d., respectively.
Again, hyperthermia combined with MMC and MISO as
well as MMC and MTR resulted in a marked decrease in
tumour DNA biosynthesis compared to the control
(P=0.00090 and P=0.0037, respectively).
Table I Tumour tripling time of ST-2 tumour
Experiment A Experiment B
Tumour volumetric Tumour growth delay Tumour volumetric Tumour growth delay
Experimental tripling time (treated-control) tripling time (treated-control)
group (days) (days) (days) (days)
Control 4.6+0.7a 4.5+ 1.oa
Heat only 6.6+0.5 2.0 6.9+0.9 2.2
MMC only 5.1+0.7 0.5 5.3+1.0 0.8
MMC+MTR 6.0+0.9 1.4 6.0+0.7 1.5
MMC+MISO 7.4+0.8 2.8 7.2+0.9 2.7
MTR only 5.5+0.7 0.9 NDb
MTR+heat 8.2+0.9 3.6 7.4+ 1.2 2.9
MISO only 6.0+0.8 1.4 6.3+0.9 1.8
MISO+heat 7.9+1.2 3.3 8.0+1.3 3.5
MMC+heat 9.5+0.8 4.9 9.7+1.0 5.2
MMC+MTR+heat 10.9+1.1 6.4 (9.9)C 12.4+1.4 7.9 (9.6)c
MMC+MISO+heat 16.6+1.3 12.0 (11.0) 18.0+1.9 13.5 (11.4)
aMean+s.d.; bNot determined; cExpected tumour growth delay.
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Discussion
Two derivatives of nitroimidazole used as chemosensitizers
did not enhance the antitumour efficacy of MMC, yet when
given in combination with hyperthermochemotherapy using
MMC, MISO showed an enhanced antitumour activity. The
regimen used was determined by the thermotolerance and
growth rate of the ST-2 tumour as well as the tolerance for
hyperthermia of nude mice. Thermotolerance of the ST-2
tumour disappears 6-7 days after hyperthermia, but by 48h
thermotolerance has decreased by about half of the maxi-
mum (Fujimoto et al., 1987). To avoid this thermotolerance,
a 6 day interval regimen would seem more satisfactory, but
this time is too long to be compatible with assessing the
growth inhibition of the ST-2 tumour. Therefore we adopted
a 48 h interval regimen.
Although the mechanisms involved in radiosensitization
with nitroimidazole are not clear, it has been reported that
the nitroimidazole derivative has greater activity on the
cytotoxic effects of radiation on hypoxic cells than aerobic
cells (Stratford, 1982; Brown & Lee, 1980; Adams, 1981).
Olive (1979) noted in in vitro experiments using mouse L
cells that these two compounds had little effect on DNA
damage, under aerobic conditions, but under anaerobic
conditions both produced marked DNA damage and
proliferation ceased.
Unlike non-malignant tissues, the blood flow in malignant
tumours decreased markedly with hyperthermia and oxygen
tension in the tumour decreased (Bicher et al., 1980; Song et
al., 1980). Despite these findings, suppression of growth in
ST-2 tumours was not observed with MISO or MTR alone.
Since the ST-2 tumour was small when exposed to hyper-
thermia, the expected decline in blood flow may not have
occurred. However, the rapid growth rate of the ST-2
tumour in small (20g) nude mice made it impractical to
carry out heat therapy in larger tumours.
With regard to the chemosensitizing activity of MISO and
MTR (Sheldon et al., 1982; Twentyman & Workman, 1982;
Milas et al., 1983), it was observed in in vivo experiments
with murine tumours that antitumour drugs, i.e., hydroxy-
urea, cyclophosphamide, melphalan, adriamycin, etc. had an
enhanced effect when given with MISO or MTR, though
MTR is less active than MISO (Twentyman & Workman,
1982), while little effect was seen with CDDP, vincristine, 5-
FU, and bleomycin. This potentiating activity was also
influenced by the time interval between the administration of
MISO and antitumour drugs (Sheldon et al., 1982).
Siemann (1982) reported that the combination of CCNU
and MISO exerted an antitumour effect on murine tumours,
but this was not the case with CCNU and MTR. In
contrast, Rajaratnam et al. (1982) reported that in a
hyperthermic treatment at 41°C, MISO exhibited a smaller
degree of cytotoxicity than MTR, when both these drugs
were given in equitoxic concentrations. As shown in Table I,
MTR is clearly less effective than MISO in combination with
MCC. MISO itself apparently has no antitumour activity.
These results are attributed to the minimal antitumour effect
of MMC on ST-2 tumours, with only two treatments, and
the short doubling time of ST-2 tumours.
There is little documentation on hyperthermo-
chemotherapy combined with nitroimidazoles, while the
combined use of hyperthermia and nitroimidazoles has been
reported. Stone (1978) and Honess et al. (1978) reported that
in in vivo experiments with murine tumours, local hyperther-
mia combined with MISO resulted in a delay in tumour
growth. Hall et al. (1977) and Rajaratnam et al. (1982)
reported that malignant cells cultured at high temperature
showed a marked decrease in growth rate in the presence of
MISO or MTR. In the present study, the combination of
hyperthermia and MTR did not enhance the antitumour
activity, while hyperthermia combined with MISO and
MMC resulted in a significant delay in tumour growth. In
contrast, hyperthermia with MTR and MMC did not
produce any tumour growth delay in excess of that found
with hyperthermochemotherapy only.
Among hypoxic radiosensitizers, i.e., MISO and MTR, the
higher the electron affinity, the more potent is the radiation
sensitization (Adams et al., 1976). MISO is a considerably
more potent radiosensitizer than MTR (Denekamp et al.,
1974). The cytotoxic efficacy of the nitroimidazole appears
to depend on the cytotoxic action of nitro radicals or other
nitro intermediates, and elevated temperatures can result in
an increased uptake of MISO and an increase in the
metabolites (Brown et al., 1983).
Although tumour tripling time in the heat only group was
prolonged by 1.5 days compared with the MMC only group,
DNA biosynthesis did not differ between the both groups.
Again, DNA biosynthesis in the MISO plus MMC plus heat
group was the same as that of the MMC plus heat as well as
the MTR plus MMC plus heat groups, yet tumour growth
delay of the MISO plus MMC plus heat group was 5.5 and
7.5 days, compared to the MTR plus MMC plus heat as well
as MMC plus heat groups, respectively. These inconsistent
results are attributed to (1) the difference in mechanism of
antitumour action between MMC and hyperthermia, (2) the
time point at which DNA biosynthesis was measured. In
mechanism of action, MMC acts directly on DNA by cross-
linking (Iyer & Szybalski, 1963), while although hyper-
thermia results in marked inhibitions of DNA and protein
synthesis (Palzer & Heidelberger, 1973), DNA repair is
relatively fast following hyperthermic damage (Gerweck et
al., 1975). Concerning the assay of DNA biosynthesis, in the
combined hyperthermic treatments showing temporary
tumour regression, DNA biosynthesis measurements should
be performed daily.
Our findings on the antitumour effect of hyperthermo-
chemotherapy combined with MISO may be the result of an
additive phenomenon of thermo-chemosensitization in vivo
hyperthermochemotherapy, because MISO exerted little
effect with chemotherapy only and only a slight effect with
hyperthermia. This effective hyperthermic enhancement with
MISO of the antitumour efficacy of MMC for human gastric
cancer transplanted into nude mice has proven effective as
an aggressive treatment composed of a combination of
surgery and subsequent hyperthermochemotherapy, for
patients with peritoneal implantation from gastric cancer
(Kokubun et al., 1987).
We thank M. Ohara of Kyushu University for comments on the
manuscript.
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